1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 14
1.2 List of Figures 26
2 Introduction 30
2.1 Catalyst 30
2.2 Related Reports 30
2.3 Upcoming Related Reports 31
3 Disease Overview 32
3.1 Etiology and Pathophysiology 32
3.2 Classification or Staging Systems 36
3.3 Symptoms 39
3.4 Prognosis 40
3.5 Quality of Life 42
4 Epidemiology 43
4.1 Disease Background 43
4.2 Risk Factors and Comorbidities 44
4.3 Global Trends 46
4.4 Forecast Methodology 49
4.5 Epidemiological Forecast for NSCLC (2015-2025) – Base Forecast 72
4.6 Epidemiological Forecast for NSCLC (2015-2025) – Alternate Forecast 86
4.7 Discussion 89
5 Disease Management 92
5.1 Diagnosis and Treatment Overview 92
5.2 US 102
5.3 France 103
5.4 Germany 104
5.5 Italy 105
5.6 Spain 106
5.7 UK 107
5.8 Japan 108
5.9 China 109
6 Competitive Assessment 110
6.1 Overview 110
6.2 Product Profiles – Major Brands, Epidermal Growth Factor Receptor-Targeting 112
6.3 Product Profiles – Major Brands, Anaplastic Lymphoma Kinase-Targeting 160
6.4 Product Profiles – Major Brands, Monoclonal Antibodies 181
6.5 Product Profiles – Major Brands, Other 216
6.6 Chemotherapies 231
7 Unmet Needs Assessment and Opportunity Analysis 233
7.1 Overview 233
7.2 First-Line Treatments That Extend Overall Survival in Advanced-Stage Nonsquamous NSCLC Without Actionable Mutations 235
7.3 Therapies Targeting Novel Biomarkers 238
7.4 Treatment Options for Squamous Patients in the First-Line and Third-Line Setting 242
7.5 Alternative Testing Options for Patients with Insufficient Biopsy Material 247
7.6 Treatments for Patients with Acquired Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance 251
8 Pipeline Assessment 256
8.1 Overview 256
8.2 Promising Drugs in Clinical Development 258
8.3 Promising Drugs in Early-Stage Development 423
9 Current and Future Players 447
9.1 Overview 447
9.2 Trends in Corporate Strategy 452
9.3 Company Profiles 455
10 Market Outlook 478
10.1 Global Markets 478
10.2 US 485
10.3 5EU 492
10.4 Japan 499
10.5 China 505
11 Appendix 512
11.1 Bibliography 512
11.2 Abbreviations 558
11.3 Methodology 569
11.4 Forecasting Methodology 569
11.5 Primary Research – KOLs 596
11.6 About the Authors 600
11.7 About GlobalData 603
11.8 Disclaimer 603